Europe Breast Cancer Market Research Report Information By Therapy (Targeted Therapy {Adotrastuzumab Emtansine, Everolimus, Trastuzumab, Abemaciclib, Ribociclib, Palbocicib, Pertuzumab, Olaparib, and Others}, Hormonal Therapy {Selective Estrogen Receptor Modulators, Estrogen Receptor Downregulators, Aromatase Inhibitors, Chemotherapy [Epothiones, Taxanes, Alkylating agents, Anthracyclines, Anti-metabolites], and Immunotherapy}, Surgery & Radiation Therapy, and Biologic Therapy), By Cancer Type (Hormone Receptor, and HER2+), By Distribution

Europe Breast Cancer Market Overview

Europe breast cancer market size was valued at USD 1.5 billion in 2022. The breast cancer industry is anticipated to expand from USD 1.57 Billion in 2023 to USD 2.28 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.80% during the forecast period (2023 - 2032). Increased research and development with an expanded number of treatments launched by the major market players and increased support from the government for integrating new treatments are major market drivers driving the breast cancer market in Europe.

Source: Secondary Research, MRFR Database, Primary Research, and Analyst Review

Breast Cancer Market Trends

• Increasing prevalence of breast cancer drives market growth.

The European breast cancer market CAGR is expanding due to the rising prevalence of breast cancer worldwide, which is expected to lead to a large number of patients in need of accurate and effective treatment options. Breast cancer is one of the most common cancers in the world, and better diagnostics are expected to increase the number of patients diagnosed in the future. New technologies in development with cutting-edge features created in treatments and improved treatment efficacy are major elements in the market value growth. The breast cancer market is expanded by increased medication advancements, new product releases by major market participants, improved treatment outcomes seen in patients, greater efficacy and effectivity of the drugs, and newly created therapies used for the disease.

Furthermore, the government's increased support for the incorporation of new treatments and medications in the healthcare industry and the rise in the incidence of breast cancer among people as a result of decreased exercise decreased obesity, increased alcohol consumption, hormone problems, menopause, and family histories of cancer. Increase government benefits by developing more policies, such as reimbursement policies, so common people can profit from expensive treatments. This contributes to the growth of the breast cancer market by introducing new regulations and improving cost-effectiveness, driving the breast cancer market revenue.

Breast Cancer Market Segment Insights

Breast Cancer Therapy Insights

The Europe breast cancer market segmentation, based on the therapy, includes targeted therapy {abemaciclib, adotrastuzumab emtansine, everolimus, trastuzumab, ribociclib, palbocicib, pertuzumab, olaparib, and others}, hormonal therapy {selective estrogen receptor modulators, estrogen receptor downregulators, aromatase inhibitors, chemotherapy [epothiones, taxanes, alkylating agents, anthracyclines, anti-metabolites], and immunotherapy}, surgery & radiation therapy, and biologic therapy. The targeted therapy segment dominated the market due to the growing understanding of molecular profiles and genetic factors in breast cancer, which permits more precise treatment approaches. Targeted therapies, including monoclonal antibodies and hormone therapies, deliver enhanced efficacy with fewer side effects, driving advancements in breast cancer care across Europe and promoting a shift towards personalized and targeted therapy strategies.

Breast Cancer Type Insights

The European breast cancer market segmentation, based on the cancer type, includes hormone receptors and HER2+. The hormone receptor segment dominated the market over the projected period. Hormone receptor status, especially estrogen and progesterone receptors, suggests treatment decisions, allowing personalized therapies like hormone receptor-positive breast cancer treatments. The emphasis on precision medicine and targeted therapies improves patient outcomes, making hormone receptor investigation a cornerstone in the management of breast cancer across Europe. Advancements in understanding receptor biology contribute to ongoing developments and improvements in breast cancer treatment strategies.

Figure 1: Europe Breast Cancer Market, by Cancer Type, 2022 & 2032 (USD Billion)

Source: MRFR Database, Secondary Research, Primary Research, and Analyst Review

Breast Cancer Distribution Channel Insights

The European breast cancer market segmentation, based on distribution channels, includes hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacy category dominated the market due to the extended dependence of the patients on the medications required for chemotherapy. Expanded demands from patients for numerous medications and improved availability of the medication in hospital pharmacies help to support the growth of the European breast cancer market.

Breast Cancer Country Insights

The European breast cancer market thrives due to the high number of cancer cases and the large number of clinical trials being executed in the region. Advanced developed technologies in the market with an expanded number of treatments available for treating breast cancer with an expansion in the number of patients help to propel the market growth with expanded government initiative in developing recent drug developments and increased efficacy of the medications with expanded results support to enhance the market growth. Screening programs, research initiatives, and improved treatment options contribute to higher survival rates, accentuating the need for breast cancer-related services. Collaborations between healthcare organizations and pharmaceutical businesses further fuel innovation. With a priority on personalized medicine and patient-centric care, the European breast cancer market shows a dynamic landscape shaped by ongoing investigation, technological progress, and a commitment to improving patient outcomes.

Figure 2: EUROPE BREAST CANCER MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Breast Cancer Key Market Players & Competitive Insights

Leading market participants invest heavily in research and development to extend their product lines, allowing the breast cancer market to grow even more. Market participants are also undertaking numerous strategic activities to extend their footprint, with significant market outcomes including new product expansions, contractual agreements, mergers and acquisitions, more elevated investments, and collaboration with other organizations. The breast cancer industry must offer cost-effective items to enhance and survive in a more competitive, expanding market climate.

Major Participants in the breast cancer market are attempting to expand market needs by investing in research and development operations, including Merck & Co, Bristol Myers Squibb, Kyowa Kirin, Eisai Co.Ltd, Sanofi, AstraZeneca, Pfizer Inc, Novartis AG, Eli Lilly and Company, GlaxoSmithKline, and Baxter Healthcare Corporation.

Key participants in the Breast Cancer market include

• Merck & Co


• Bristol Myers Squibb


• Kyowa Kirin


• Eisai Co.Ltd


• Sanofi


• Pfizer Inc


• AstraZeneca


• Novartis AG


• Eli Lilly and Company


• GlaxoSmithKline


• Baxter Healthcare Corporation

Breast Cancer Industry Developments

June 2021: Genetech collaborated with Nykode (Vaccibody) to develop novel DNA-based cancer vaccines. This global oncology collaboration between Nykode and Genentech aims to develop individualized neoantigen cancer vaccines across multiple tumor types.

Breast Cancer Market Segmentation

Breast Cancer Therapy Outlook

• Targeted Therapy
  
  
  
  • Abemaciclib
  
  
  • Ado-trastuzumab Emtansine
  
  
  • Everolimus
  
  
  • Trastuzumab
  
  
  • Ribociclib
  
  
  • Palbociclib
  
  
  • Pertuzumab
  
  
  • Olaparib
  
  
  • Others
  
  
  
  


• Hormonal Therapy
  
  
  
  • Selective Estrogen Receptor Modulators
  
  
  • Aromatase Inhibitors
  
  
  • Estrogen Receptor Downregulation
  
  
  • Chemotherapy (Epothiones, Taxanes, Alkylating Agents, Anthracyclines, Anti-Metabolites)
  
  
  • Immunotherapy
  
  
  
  


• Surgery and radiation therapy


• Biologic Therapy

• Hormone Receptor


• HER2+

Breast Cancer Distribution Channel Outlook

• Hospital Pharmacies


• Retail Pharmacies


• Online Pharmacies


• Others

Breast Cancer Regional Outlook

• Europe


• China


• Japan


• India


• Australia


• South Korea


• Indonesia


• Thailand


• Vietnam


• Malaysia


• Singapore


• Rest of Europe